In this week’s View, Dr. Eagle looks at contemporary outcomes and trends for the transseptal mitral valve-in-valve procedure ...

Medical therapy is critical in preventing the worst complications of peripheral artery disease (PAD), among them heart attack ...

Beta-blocker use did not result in a lower incidence of composite death or new AMI, all-cause death, AMI, or heart failure ...

Rivaroxaban did not reduce the incidence of cognitive decline, stroke or transient ischemic attack (TIA) in patients younger than 65 with nonvalvular atrial fibrillation (AFib) and low risk for stroke ...

Left atrial appendage closure (LAAC) in patients at moderate to high risk for stroke who were undergoing catheter atrial fibrillation (AFib) ablation resulted in significantly less bleeding compared ...

The BRAIN-AF trial failed to show that rivaroxaban prevents cognitive decline, stroke, or TIA among patients with AF. The primary outcome, cognitive decline (defined by a ≥2-point reduction in ...

A late-breaking session at AHA 2024 highlighted new research focusing on "Smart Cardiology" innovations, including artificial intelligence (AI), aimed at improving heart health. In the PHARM-HF A&F ...

Among patients with ischemic cardiomyopathy and ventricular tachycardia (VT), catheter ablation as a first-line strategy over antiarrhythmic drugs (AAD) was associated with a lower risk of the primary ...

The OPTION trial showed that left atrial appendage closure after AF ablation was associated with a lower risk of non–procedure-related major or clinically relevant nonmajor bleeding compared with oral ...

The following are key points to remember from an American Heart Association scientific statement on the diagnosis and management of Kawasaki disease: ...

In patients with obesity and heart failure with preserved ejection fraction (HFpEF), weekly treatment with tirzepatide over approximately two years reduced the risk of worsening heart failure events, ...